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Background: Recently, the orphan G-protein coupled receptor 83 (GPR83) was identified as a new participant in
body weight regulation. This receptor is highly expressed in the hypothalamic arcuate nucleus and is regulated in
response to nutrient availability. Gpr83 knock-out mice are protected from diet-induced obesity. Moreover, in a
previous study, we designed and characterized several artificial constitutively activating mutations (CAMs) in GPR83.
A particular CAM was located in the extracellular N-terminal domain (eNDo) that is highly conserved among GPR83
orthologs. This suggests the contribution of this receptor part into regulation of signaling, which needed a more
detailed investigation.
Findings: In this present study, therefore, we further explored the role of the eNDo in regulating GPR83-signaling
and demonstrate a proof-of-principle approach in that deletion mutants are characterized by a strong increase in
basal Gq/11-mediated signaling, whilst none of the additionally characterized signaling pathways (Gs, Gi, G12/13)
were activated by the N-terminal deletion variants. Of note, we detected basal GPR83 MAPK-activity of the wild
type receptor, which was not increased in the deletion variants.
Conclusions: Finally, the extracellular portion of GPR83 has a strong regulatory function on this receptor. A suppressive
- inverse agonistic - effect of the eNDo on GPR83 signaling activity is demonstrated here, which also suggests a putative
link between extracellular receptor activation and proteolytic cleavage. These new insights highlight important aspects
of GPR83-regulation and might open options in the development of tools to modulate GPR83-signaling.
Keywords: G-protein coupled receptor 83, Signaling mechanism, Inverse agonist, Antagonist, Constitutive activationIntroduction
G-protein coupled receptors (GPCRs) are involved in
regulating the flow of information across membranes,
they are tuning components of the cellular-physiological
machinery and serve as hubs for signal transduction
between different biological units [1]. This information
flow subsequently results in specific physiological or, in
the event of dysregulation, pathophysiological reactions [2].
GPCRs and their respective ligands can be multi-key
players, which are often simultaneously related to different
processes and might be responsible to synchronize or* Correspondence: heike.biebermann@charite.de; gunnar.kleinau@charite.de
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and neurobiology).
Many different GPCRs have been identified to be in-
volved in the regulation of metabolism and body weight
such as the melanocortin-4 receptor (MC4R) or the
ghrelin receptor (GHSR) (reviews [3,4]). Of note, obesity
is the most common preceding health condition leading
to many concomitant health disorders, including type 2
diabetes mellitus, hypertension, arteriosclerosis, several
types of cancer, polycystic ovarian syndrome or sleep
apnea [5]. Obesity should be considered as a disease [6],
which has globally attained epidemic proportions over
the last decades and is no longer restricted to developed
countries [4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recently identified as a new determinant involved in
body weight regulation [9]. This orphan receptor is most
abundantly expressed in the thymus and brain [8,10,11].
GPR83 has been previously found to be involved in the
control of circulating adiponectin levels [7]. The en-
dogenous ligand of GPR83 remains to be identified.
Our recently published studies have deciphered several
new functional and physiological properties of GPR83.
Briefly, GPR83 is involved in systemic energy metabolism
via ghrelin-dependent and ghrelin-independent mecha-
nisms [9]. This receptor is highly expressed in the hypo-
thalamic arcuate nucleus, and it has been demonstrated
that hypothalamic expression of Gpr83 is dependent
on nutrient availability. Moreover, Gpr83 expression is de-
creased in obese compared to lean mice and constitutes
homodimers but also has the capacity for heterodimeriza-
tion (e g. with the ghrelin receptor) [12]. Basal Gq/11
related signaling activity has been shown for Gpr83 as well
as slight activation or stabilization of the active conform-
ation using Zn(II) supplementation. We recently designed
several artificial constitutively activating mutations (CAMs)
[12], whereby a particular CAM was located in the extracel-
lular N-terminal domain (eNDo) that is highly conserved
among GPR83 orthologs. In this current study, we fur-
ther explored the contribution of the eNDo region on
GPR83-signaling in order to advance insights into theFigure 1 Sequence comparison of GPR83 othologs and designed GPR
orthologs for comparison and identification of sequence conservation
colors. High conservation is also indicative for a specific fold and/or functio
(between positions 36–65) is highly conserved among the compared varian
green – hydrophobic, blue – positively charged, red – negatively charged. Th
GPR83 deletion mutants: The experimentally deleted parts are highlighted: a.
signal peptide is indicated as SP and the hemagglutinin tag with HA.GPR83-signaling mechanism. For this purpose, deletion
constructs of the eNDo were designed and functionally
characterized.
Findings
In this study, we aimed to unravel the role of the GPR83
N-terminal domain on receptor function, which was ini-
tially tested using deletion constructs. All constructs
retained the GPR83 signal peptide and had an adjacent
HA-tag to monitor cell surface expression levels. We
deleted residues 18–35 or the entire eNDo (residues 18–
65) as well as an internal peptide sequence consisting of
residues 36–65 (Figure 1A and B). These three GPR83
constructs were functionally characterized with regard
to their basal signaling activity and cell surface expression
levels. In addition, a previously identified Gq/11-CAM
(single point mutation H331A [12] in the transmembrane
helix (TMH) 7) was used for comparison.
The cell surface expression level of the Gpr83 deletion
constructs is differently modified
Cell surface expression of the deletion constructs (Figure 2)
were either found to be comparable with wild type GPR83
expression level (deletion variant del18-35) or slightly de-
creased (del36-65, 72% of wild type receptor). On the
other hand, the cell surface expression level for del18-65
was observed to be strongly decreased to 19% of wild83 variants A) Alignment of N-terminal amino acids of GPR83
. Regions of conservation can be recognized by the overlapping
n. It is evident that especially the second half of the N-terminal tail
ts. Different colors of amino acids indicate their biophysical properties:
e alignment was visualized using BioEdit. B) Schematic representation of
deletion 18–35, b. deletion 36–65, c. deletion 18–65. The position of the
Figure 2 Cell surface expression levels of different N-terminal GPR83 deletion mutants compared to wild type GPR83 which was set to
100% (absorption (492/620): 0.31 ± 0.01). The Gpr83 variants were detected using an HA-ELISA system as previously reported [12]. Untagged
GPR83 served as the negative control. Data were assessed from a minimum of three independent experiments, each performed at least in
triplicate, and are represented as mean + SEM. ***p≤ 0.001 (unpaired t-test, two-tailed).
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structural features and a high level of induced constitutive
signaling activity (Figure 3).Deletion of the entire extracellular domain leads to high
constitutive Gq/11-activation
Despite the detection of low levels of receptor cell-surface
expression, removal of the entire eNDo of GPR83 resulted
in an approximately four-fold increase in basal Gq/11-
signaling activity (Figure 3A), indicating a dramatic increase
in basal activity. This increase in basal activity was also
confirmed for a receptor variant without an N-terminally
fused tag (not shown), which excludes an influence of the
receptor-function by this modification.
Deletion of the C-terminal part of the eNDo (between
positions 36–65, Figure 3A) constitutively activates GPR83
to levels comparable to the H331A-CAM in TMH7, with a
1.4-fold increase over basal activity (Figure 3A). In con-
trast, deletion of the first half of the eNDo (del18-35)
decreased basal Gq/11-signaling to approximately 60% of
wild type GPR83 (Figure 3A), which indicates an inverse
agonistic effect of this deletion on basal GPR83-activity.GPR83 basal MAPK-signaling can be increased by a single
point mutation in TMH7
We next investigated whether GPR83 was able to acti-
vate MAPK-signaling. Indeed, GPR83 was found to
mediate a basal level of MAPK-activity (Figure 3B). Sur-
prisingly, deletion of position 18–35 resulted in impaired
basal MAPK-signaling (Figure 3B), which was also ob-
served for Gq/11-signaling. In contrast, the removal of
the entire eNDo or the internal peptide (position 36–65)
did not alter MAPK/ERK-activation in comparison to
wild type GPR83 (Figure 3B). A two-fold increase in
MAPK-activity was detected for the H331A CAM, indi-
cating that MAPK-signaling may be regulated by resi-
dues in the transmembrane region. Thus, the structural
requirements for activation of MAPK and Gq/11 signal-
ing by GPR83 are distinct and regulated by different
domains.
In addition, we analyzed G12/13- as well as Gs/Gi-
signaling but could not detect any activity for wild type
GPR83 or for any of the N-terminal deletion mutants in-
vestigated (Figures 3C/D). In order to detect Gi-activity,
the adenylyl cyclase enhancer forskolin was used to
produce increased cAMP levels. Any mutation causing
Figure 3 Different N-terminal GPR83 deletion mutants were functionally characterized and compared with the wild type GPR83 (A/B)
or an empty vector control (pcDps, B/C/D). Shown are Gq/11-activation in A), MAPK-activation in B), G12/13-activation in C) and Gs/Gi-signaling
properties in D). Wild type GPR83 serves as a positive control for Gq/11-signaling (A). The TSH-stimulated TSHR serves as a positive control for MAPK- and
G12/13-signaling (B/C). Forskolin-stimulation shows Gs-activity of the used cell line by activating adenylyl cyclase. A decreased value of forskolin-stimulation
in comparison to the empty vector control would indicate inhibitory Gi-activity. Data were evaluated from a minimum of three independent experiments,
each performed at least in triplicate. Data were calculated as fold over the empty vector control, set to 1 (A: 4828.67 ± 1165.71, B: 1334800 ±
326986.69, C: 2095559.89 ± 447919.48 relative light units; D: 2.03 ± 0.15 nM cAMP). Data represent mean + SEM. *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001 (unpaired t-test, two-tailed).
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crease forskolin-stimulated cAMP values below the
empty vector control, this was however not observed,
thus Gi coupling can be excluded.
Discussion
The entire N-terminal part of GPR83 is likely a domain
that functions as an inverse agonist of Gq/11-mediated
signaling
The complete deletion of the N-terminal extracellular
part of GPR83 specifically induces the constitutive acti-
vation of Gq/11-signaling by this receptor. In contrast,
Gs, Gi or G12/13-related pathways or MAPK-signaling
were not activated. This indicates that the extracellular
N-terminus of GPR83 has evolved to stabilize an inactive
receptor conformation and thus serves as an intramo-
lecular inverse agonist (schematized in Figure 4A). Of
note, the GPR83 variant del18-35 revealed cell surface
expression levels similar to the wild type receptor, while
the highly active del18-65 full deletion variant is charac-
terized by low cell surface expression levels of approxi-
mately 20% of the wild type receptor (Figure 2). Thehigh conservation of amino acids throughout several
GPR83 orthologs, especially in the second N-terminal
half of GPR83 (Figure 1A), supports the assumption of a
functionally important region that might also be charac-
terized by a specific structural fold. We assume that
interactions from the N-terminal domain to additional
regions of the receptor exist, most likely with the extra-
cellular loops in order to maintain a (partially) inactive
basal receptor conformation (Figure 4). Removal of the
entire eNDo would lead to an active receptor conform-
ation as N-terminal interactions with the accessible
extracellular receptor loops should be released (Figure 4).
Interestingly, activation of TSHR by deletion of the en-
tire eNDo or extracellular fragments leads also to consti-
tutive signaling activity [13-15], and suggests an inverse
agonistic function of the TSHR-eNDo.
Different N-terminal receptor fragments with specific
properties
At this stage, we cannot provide data to explain the de-
creased basal signaling activity caused by the deletion of
residues 18–35, an effect which contradicts the findings
Figure 4 Structural scheme of GPR83 and variants with indicated findings and derived hypotheses. A) In wild type GPR83, the N-terminal
domain (eNDo) is stabilized intramolecularly by side-chain interactions between specific amino acids (red broken lines). The eNDo might have a
defined structural fold, which is indicated by high amino acid conservation throughout GPR83 orthologs (Figure 1). The eNDo most likely interacts
with the extracellular loops (E’s 1–3) and these interactions probably maintain the basal state. B) In contrast, deletion of residues 18–35, a partial
deletion, increases the inverse agonistic effect of the remaining eNDo residues on GPR83 and suppresses basal activity, by presumptively stabilizing the
inactive conformation. C) Deletion of residues 35–65 of the eNDo leads to slight receptor activation, possibly due to the partial loss of intramolecular
interactions with the extracellular loops. D) The GPR83 becomes highly active following removal of the entire N-terminal domain. Ctt = C-terminal tail,
I = intracellular loop, E = extracellular loop.
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only be speculated that the deletion of residues 18–35
strengthens the interactions between residues 36–65 e.g.
with the extracellular loops of GPR83, resulting in an
enforced inactive conformation leading to a further loss
of basal activity.
Interestingly, only the removal of the entire eNDo was
found to result in a high activation, whereas the other
two shorter deletion mutants analyzed demonstrated
either only weak activity or a lack of constitutive activity
(Figure 4B, C). The data point to a more complex inter-
play between the different receptor parts either intra- or
intermolecularly.
The MAPK pathway and Gq/11 signaling are regulated
differently
For the first time, we demonstrate basal MAPK activity
for GPR83, which is impaired upon deletion of residues
18–35. In contrast to the findings for Gq/11-signaling
activity, removal of the entire eNDo or residues 35–65
displayed constitutive MAPK-activity levels seen for wild
type GPR83. However, the H331A-CAM mutation, lo-
cated in TMH7, showed constitutive activation of the
MAPK pathway. In conclusion, activation of Gq/11 by
GPR83 can be induced by modification of the extracellu-
lar domain, but MAPK-signaling is not induced by thisevent and can be forced by a single CAM in the trans-
membrane region. The data may indicate differences in
the detailed activation mechanism of diverse signaling
pathways activated by GPR83.
Conclusions and open questions
Finally, the extracellular portion of GPR83 has a strong
regulatory function on this receptor. A suppressive -
inverse agonistic - effect of the eNDo on GPR83 signaling
activity is demonstrated here, which also suggests a
putative link between extracellular receptor activation
and proteolytic cleavage in vivo.
As the work presented here has opened several new
perspectives on this receptor with regards to signaling
mechanisms and regulation, the following summary
highlights open questions of great interest in warranting
their further research:
 We do not know the exact interplay between the
extracellular parts of GPR83 or relationship between
single amino acids and activity regulation. It would be
of great interest to further narrow down the
particularly important structural determinants of the
inverse agonist activity observed for the eNDo domain.
 The maximal level of GPR83-signaling activity
remains to be identified, due to an unknown
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The constitutive activity attained following full-length
deletion of the eNDo may or may not be maximal,
and we cannot exclude that other pathways as found
here may be activated by the physiological ligand.
 Potentially, the eNDo domain may also act
like a ligand recognition motif, as has been
observed for the ligands TSH and thyrostimulin
of the TSHR (reviewed in [16]), which is also
a class A GPCR with a long extracellular
N-terminal region. However, we cannot address
this in the absence of an endogenous ligand for
GPR83.
 The contribution of a dimeric constellation
(intermolecular interactions) on signaling regulation
remains unknown. Our findings may also
conceivably be related to a modified interplay
between protomeric GPR83 interactions in dimeric
(oligomeric) constellations.
 For endogenous GPR83-activation, we hypothesize
that a specific N-terminal region of GPR83 might be
recognized and cleaved/clipped by a protease.
Potential enzyme candidates are disintegrin,
metalloproteinase ADAM 10 (A Disintegrin And
Metalloproteinase 10) [17] or trypsin [18],
whereby ADAM 10 does potentially cleave but not
activate TSHR (reviewed in [19]). Moreover,
positively charged amino acid side chains are
recognition motifs for trypsin [20]. Such positively
charged residues (such as arginines) are also
present in a cluster-like manner in the eNDo of
GPR83 (Figure 1).
In addition, it is known that the G-protein coupled
protease-activated receptors (PARs) become active
following cleavage by serine proteases such as
thrombin [21]. In conclusion, tests with proteolytic
enzymes are required in order to unravel their
potential contribution on GPR83 activation or
signaling.
 For both the TSHR [13] and PARs, it has been
described that fragments of the eNDo (with (PARs)
or without (TSHR) cleavage) function as an
intramolecular agonist. This contribution of the
GPR83-eNDo for the endogenous activation
mechanism remains ambiguous.
 Other GPCRs coupled to Gq/11 (e.g. the
angiotensin II receptor or the α-adrenergic 2
receptor [22,23]) have exhibited their involvement
in stimulating the activation of metalloproteinases
for shedding of further proteins [22] and/or
activating signaling pathways such as MAPK [23].
Therefore, a future interest would be to investigate
the contribution of ADAMs as downstream
effectors or activating proteases of GPR83.Finally, our findings open new perspectives for GPR83
related research by advanced insights into structure-
function relationships.
Materials and methods
Construction of wild type and mutant receptors
Cloning of Gpr83 was performed as recently described
[12]. Gpr83 was amplified from murine hypothalamic
cDNA and, as control for functional assays, thyroid stimu-
lating hormone receptor (TSHR) () was cloned from hu-
man thyroid cDNA. Receptor-cDNAs were cloned into
the pcDps expression vector. A hemagglutinin tag was
cloned downstream of the signal peptide of Gpr83 (SP-
HA, see Figure 1B for schematic representation). The
H331A mutation of Gpr83 was generated by site-directed
mutagenesis. The deletion mutants were created by
successive fractional cloning (Figure 1B). Automatic
sequencing was used to determine the accuracy of the
PCR-derived products. The pGL4.30[luc2P/NFAT-RE/
Hygro], pGL4.33[luc2P/SRE/Hygro] and pGL4.34[luc2P/
SRF-RE/Hygro] reporter constructs, co-transfected for
Gq/11, MAPK (mitogen-activated protein kinase) or G12/
13 (Rho A) determination, were purchased from Promega
(Mannheim, Germany).
Cell culture and transfection
COS-7 cells were cultured in Dulbecco’s modified medium
(DMEM/Biochrom, Berlin, Germany), whereas HEK293
cells were cultured in minimal Essential medium (MEM/
Biochrom, Berlin, Germany), and both were supplemented
with 10% fetal bovine serum, 100 U/ml penicillin, and
100 μg/ml streptomycin and incubated at 37°C in a
humidified 7% CO2 incubator. For measurement of
Gq/11-, MAPK- and G12/13-activity via reporter gene
assay, HEK293 cells were seeded into 96-well plates
(1.5 × 104 cells/well), coated with poly-L-lysin (Bio-
chrom, Berlin, Germany). For Gs/Gi determination,
COS-7 cells were seeded into 96-well plates (0.9 × 104
cells/well). Transfection was performed with 41.7 ng of re-
ceptor plasmid-DNA/well and 0.5 μL Metafectene™/well
(Biontex, Martinsried, Germany) one day after seeding.
For Gq/11, MAPK and G12/13 determination equal
amounts of the appropriate reporter construct, containing
the firefly luciferase gene, was co-transfected.
Cell surface expression studies
Cell surface expression studies of wild type GPR83 and
designed constructs were carried out in COS-7 cells and
were performed using an ELISA system that detects HA-
tagged receptors. A tag-less GPR83 served as a negative
control (detailed description in [12]). Seventy two hours
after transfection cells were washed two times with
Dulbecco’s phosphate buffered saline (DPBS, Biochrom,
Berlin) and fixed for 30 min. in 4% formaldehyde in DPBS
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in blocking buffer (10% FCS supplemented DMEM) for
1 h at 37°C followed by a washing step in DPBS cells were
incubated for 2 h in blocking buffer with 1 μg/ml biotin la-
belled anti-HA monoclonal antibody (Roche, Mannheim)
at 37°C followed by three washes in DPBS and incubation
in blocking buffer with 1 μg/ml streptavidin labelled per-
oxidase (Dianova, Hamburg) at 37°C for 1 h followed by
three times washing. The color reaction was carried out
with 0.1% H2O2 and 10 μg o-phenylendiamine in 0.1 M
citric acid and 0.1 M Na2HPO4 at pH 5.2. The reaction
was stopped after 10 min. with 1 M Na2SO3 in 1 M HCl.
Colorimetry was carried out using an anthos reader 2001
(anthos labtech instruments, Salzburg).Measurement of Gq/11, MAPK and G12/13 via reporter
gene assay
Activity of Gq/11-, MAPK- and G12/13-signaling was
determined 48 hours after transfection. The TSHR
stimulated with 100 mU/mL bovine thyroid stimulat-
ing hormone (TSH, purchased from Sigma-Aldrich,
Taufkirchen, Germany) served as a positive control in
each case [24,25]. Following six hours of stimulation,
cells were lysed with 50 μl/well of 1x Passive Lysis
Buffer (Promega). Pathway activities were determined
by luciferase activity according to the manufacturer’s
instructions (Promega).Determination of Gs- or Gi-signaling
Intracellular cAMP levels to determine Gs- or Gi-activation
were measured in COS-7 cells in the presence of 1 mM
3-isobutyl-1-methylxanthine (Sigma-Aldrich, Munich,
Germany) using AlphaScreen technology [26]. The
hTSHR stimulated with 100 mU/mL bovine TSH (Sigma-
Aldrich) served as Gs positive control [24,25]. To investi-
gate Gi-activity, cells were treated with 50 μM forskolin
(Sigma-Aldrich). After stimulation with forskolin for 45 mi-
nutes, cell lysis (50 μL/well lysis buffer) and cAMP meas-
urement were performed as previously described [12].Data analysis
Statistical analyses were performed using the statistical
tools implemented in Graph Pad Prism, version 5
(GraphPad Software, San Diego, California, USA).
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